{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:58:41Z","timestamp":1780419521755,"version":"3.54.1"},"reference-count":81,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2014]]},"DOI":"10.5582\/irdr.2014.01001","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T00:58:55Z","timestamp":1402016335000},"page":"34-45","source":"Crossref","is-referenced-by-count":58,"title":["Current treatment of atypical hemolytic uremic syndrome"],"prefix":"10.5582","volume":"3","author":[{"given":"Bernard","family":"S. Kaplan","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, The Children's Hospital of Philadelphia, and The Perelman School of Medicine at The University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"L. Ruebner","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, The Children's Hospital of Philadelphia, and The Perelman School of Medicine at The University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"M. Spinale","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, The Children's Hospital of Philadelphia, and The Perelman School of Medicine at The University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Copelovitch","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, The Children's Hospital of Philadelphia, and The Perelman School of Medicine at The University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kaplan BS, Drummond KN. The hemolytic-uremic syndrome is a syndrome. N Engl J Med. 1978; 298:964-966.","DOI":"10.1056\/NEJM197804272981710"},{"key":"2","unstructured":"2. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: Bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955; 85:905-909. (in German)"},{"key":"3","unstructured":"3. Barnard PJ, Kibel M. The haemolytic-uraemic syndrome of infancy and childhood. A report of eleven cases. Cent Afr J Med. 1965; 11:31-34."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, Bennett CL, Kwaan HC. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010; 95:1555-1562.","DOI":"10.3324\/haematol.2009.019299"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164: 759-766.","DOI":"10.1111\/bjh.12718"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985; 151:775-782.","DOI":"10.1093\/infdis\/151.5.775"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bielaszewska M, Mellmann A, Zhang W, K\u00f6ck R, Fruth A, Bauwens A, Peters G, Karch H. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study. Lancet Infect Dis. 2011; 11:671-676.","DOI":"10.1016\/S1473-3099(11)70165-7"},{"key":"8","unstructured":"8. Koster FT, Boonpucknavig V, Sujaho S, Gilman RH, Rahaman MM. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin Nephrol. 1984; 21:126-133."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Klein PJ, Bulla M, Newman RA, M\u00fcller P, Uhlenbruck G, Schaefer HE, Kr\u00fcger G, Fisher R. Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome. Lancet. 1977; 2:1024-1025.","DOI":"10.1016\/S0140-6736(77)92915-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998; 9:1126-1133.","DOI":"10.1681\/ASN.V961126"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014; 20:518-525.","DOI":"10.1016\/j.bbmt.2013.12.565"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Buddles MR, Donne RL, Richards A, Goodship J, Goodship TH. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet. 2000; 66:1721-1722.","DOI":"10.1086\/302877"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361:1676-1687.","DOI":"10.1056\/NEJMra0902814"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fr\u00e9meaux-Bacchi V, Miller EC, Liszewski MK, <i>et al<\/i>. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008; 112:4948-4952.","DOI":"10.1182\/blood-2008-01-133702"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361:345-357.","DOI":"10.1056\/NEJMoa0810739"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. J\u00f3zsi M1, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood. 2008; 111:1512-1514.","DOI":"10.1182\/blood-2007-09-109876"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Menni F, Testa S, Guez S, Chiarelli G, Alberti L, Esposito S. Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatr Nephrol. 2012; 27:1401-1405.","DOI":"10.1007\/s00467-012-2152-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Labrune P, Zittoun J, Duvaltier I, Trioche P, Marquet J, Niaudet P, Odi\u00e8vre M. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr. 1999; 158:734-739.","DOI":"10.1007\/s004310051190"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Micheletti MV, Lavoratti G, Gasperini S, Donati MA, Pela I. Hemolytic uremic syndrome and rhabdomyolysis in a patient with succinate coenzyme Q reductase (complex II) deficiency. Clin Nephrol. 2011; 76:68-73.","DOI":"10.5414\/CN106681"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Watkins D, Schwartzentruber JA, Ganesh J, Orange JS, Kaplan BS, Nunez LD, Majewski J, Rosenblatt DS. Novel inborn error of folate metabolism: Identification by exome capture and sequencing of mutations in the MTHFD1 gene in a single proband. J Med Genet. 2011; 48:590-592.","DOI":"10.1136\/jmedgenet-2011-100286"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lemaire M, Fr\u00e9meaux-Bacchi V, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45:531-536.","DOI":"10.1038\/ng.2590"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant. 2013; 13:2201-2206.","DOI":"10.1111\/ajt.12297"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Szil\u00e1gyi A, Kiss N, Bereczki C, T\u00e1losi G, R\u00e1cz K, T\u00fari S, Gy\u00f6rke Z, Simon E, Horv\u00e1th E, Kelen K, Reusz GS, Szab\u00f3 AJ, Tulassay T, Proh\u00e1szka Z. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2013; 28:2237-2245.","DOI":"10.1093\/ndt\/gft198"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Guigonis V, Fr\u00e9meaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, Mougenot B, Rosenblatt DS, Desch\u00eanes G. Late-onset thrombocytic microangiopathy caused by cblC disease: Association with a factor H mutation. Am J Kidney Dis. 2005; 45:588-595.","DOI":"10.1053\/j.ajkd.2004.12.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J. 2013; 6:421-425.","DOI":"10.1093\/ckj\/sft065"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol. 2013; 28:2097-2105.","DOI":"10.1007\/s00467-012-2383-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8:622-633.","DOI":"10.1038\/nrneph.2012.195"},{"key":"28","unstructured":"28. Novak RW, Martin CR, Orsini EN. Hemolytic-uremic syndrome and T-cryptantigen exposure by neuraminidase-producing pneumococci: An emerging problem? Paediatr Pathol. 1983; 1:409-413."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ault BH. Factor H and the pathogenesis of renal diseases. Pediatr Nephrol. 2000; 14:1045-1053.","DOI":"10.1007\/s004670050069"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Jarva H, Hellwage J, Jokiranta TS, Lehtinen MJ, Zipfel PF, Meri S. The group B streptococcal beta and pneumococcal Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J Immunol. 2004; 172:3111-3118.","DOI":"10.4049\/jimmunol.172.5.3111"},{"key":"31","unstructured":"31. Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses. 2013; 81:400-403."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis. 2014; 63:119-123.","DOI":"10.1053\/j.ajkd.2013.08.031"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ozaltin F, Li B, Rauhauser A, <i>et al<\/i>. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol. 2013; 24:377-384.","DOI":"10.1681\/ASN.2012090903"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Quaggin SE. DGKE and atypical HUS. Nat Genet. 2013; 45:475-476.","DOI":"10.1038\/ng.2622"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, Skerka C, Jokiranta TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J, Rodriguez de Cordoba S, Zipfel PF, Goodship TH. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat. 2006; 27:292-293.","DOI":"10.1002\/humu.9408"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5:1844-1859.","DOI":"10.2215\/CJN.02210310"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kaplan BS, Chesney RW, Drummond KN. Hemolytic uremic syndrome in families. N Engl J Med. 1975; 292:1090-1093.","DOI":"10.1056\/NEJM197505222922102"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Sullivan M1, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet. 2010; 74:17-26.","DOI":"10.1111\/j.1469-1809.2009.00554.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6:60.","DOI":"10.1186\/1750-1172-6-60"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kaplan BS, Garcia CD, Chesney RW, Segar WE, Giugno K, Chem R. Peripheral gangrene complicating idiopathic and recessive hemolytic uremic syndromes. Pediatr Nephrol. 2000; 14:985-989.","DOI":"10.1007\/s004670050058"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, Edefonti A. Skin Involvement in Atypical Hemolytic Uremic Syndrome. Am J Kidney Dis. 2013; doi: 10.1053\/j.ajkd.2013.09.020.","DOI":"10.1053\/j.ajkd.2013.09.020"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. A\u017eukaitis K, Loirat C, Malina M, Adomaitien\u0117 I, Jankauskien\u0117 A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol. 2013.","DOI":"10.1007\/s00467-013-2713-3"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fr\u00e9meaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011; 7:23-35.","DOI":"10.1038\/nrneph.2010.155"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013; 33:508-530.","DOI":"10.1016\/j.semnephrol.2013.08.003"},{"key":"45","unstructured":"45. Walport MJ. Complement. First of two parts. N Engl J Med. 2001; 344:1058-1066."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007; 25:1256-1264.","DOI":"10.1038\/nbt1344"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Kopp A, Strobel S, Tortajada A, Rodr\u00edguez de C\u00f3rdoba S, S\u00e1nchez-Corral P, Proh\u00e1szka Z, L\u00f3pez-Trascasa M, J\u00f3zsi M. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol. 2012; 189:1858-1867.","DOI":"10.4049\/jimmunol.1200357"},{"key":"48","unstructured":"48. Kim JJ, McCulloch M, Marks SD, Waters A, Noone D. The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies. Clin Nephrol. 2013."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011; 365:8-26.","DOI":"10.1016\/j.jim.2010.12.020"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010; 115:379-387.","DOI":"10.1182\/blood-2009-05-221549"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Wilson V, Darlay R, Wong W, Wood KM, McFarlane J, Schejbel L, Schmidt IM, Harris CL, Tellez J, Hunze EM, Marchbank K, Goodship JA, Goodship TH. Genotype\/phenotype correlations in complement factor h deficiency arising from uniparental isodisomy. Am J Kidney Dis. 2013; 62:978-983.","DOI":"10.1053\/j.ajkd.2013.05.020"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Ruebner RL, Kaplan BS, Copelovitch L. A time for reappraisal of &quot;atypical&quot; hemolytic uremic syndrome: Should all patients be treated the same? Eur J Pediatr. 2012: 171:1519-1525.","DOI":"10.1007\/s00431-012-1763-z"},{"key":"53","unstructured":"53. Noris M, Bresin E, Mele C, Remuzzi G. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews<sup>TM<\/sup> [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. (updated 2013 Aug 08)"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36:653-659.","DOI":"10.1055\/s-0030-1262887"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. European Paediatric Study Group for HUS. Pediatr Nephrol. 2009; 24:687-696.","DOI":"10.1007\/s00467-008-0964-1"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Reid VL, Mullan A, Erwig LP. Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ Case Rep. 2013; doi: 10.1136\/bcr-2013-200980.","DOI":"10.1136\/bcr-2013-200980"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013; 24:475-486.","DOI":"10.1681\/ASN.2012090884"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Legendre CM, Licht C, Muus P, <i>et al<\/i>. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368:2169-2181.","DOI":"10.1056\/NEJMoa1208981"},{"key":"59","unstructured":"59. Gaber AO, Loirat C, Greenbaum LA, Babu S, Furman RR, Sheerin NS, Cohen DJ, Eitner F, Delmas Y, Bedrosian CL, Legendre MC. Abstract: [SA-PO852] Eculizumab (ECU) Maintains Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients (Pts) with Progressing Thrombotic Microangiopathy (TMA): 3-Year (Yr) Update."},{"key":"60","unstructured":"60. Fakhouri F, Hourmant M, Campistol JM, <i>et al<\/i>. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult patients (pts) with atypical hemolytic uremic syndrome (aHUS). Presented at American Society of Nephrology (ASN) Kidney Week 2013, Atlanta, Ga., November 8, 2013. Abstract FR-OR057."},{"key":"61","unstructured":"61. Delmas Y, Loirat C, Muus P, <i>et al.<\/i> Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients (pts) with long disease duration and chronic kidney disease (CKD): Sustained efficacy at 3 years. Presented at American Society of Nephrology (ASN) Kidney Week 2013, Atlanta, Ga., November 8, 2013. Abstract FR-PO536."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Kaplan BS, Ruebner RL, Copelovitch. An evaluation of the results of eculizumab treatment of atypical hemolytic uremic syndrome. Expert opinion Orphan Drugs. 2013; 2:167-176.","DOI":"10.1517\/21678707.2013.750579"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis. 2012; 59:707-710.","DOI":"10.1053\/j.ajkd.2011.11.027"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011; 26:613-619.","DOI":"10.1007\/s00467-010-1708-6"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9:2644-2645.","DOI":"10.1111\/j.1600-6143.2009.02817.x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation. 2010; 89:903-904.","DOI":"10.1097\/TP.0b013e3181ccd80d"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation \u2013 a case report. Transplant Proc. 2011; 43:2097-2101.","DOI":"10.1016\/j.transproceed.2011.02.064"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011; 6:1488-1494.","DOI":"10.2215\/CJN.10181110"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Ch\u00e2telet V, Lobbedez T, Fr\u00e9meaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B. Eculizumab: Safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: Case report. Transplant Proc. 2010; 42:4353- 4355.","DOI":"10.1016\/j.transproceed.2010.09.125"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): An update on a previous case report. Clin Pharmacol. 2011; 3:45-50.","DOI":"10.2147\/CPAA.S23687"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C. Antibody mediated rejection associated with complement factor h-related protein 3\/1 deficiency successfully treated with eculizumab. Am J Transplant. 2012; 12:2546-2553.","DOI":"10.1111\/j.1600-6143.2012.04124.x"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouvi\u00e8re C, B\u00e9rard E, Salomon R, Fr\u00e9meaux-Bacchi V, Niaudet P, Boyer O. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol. 2014; 29:75- 83.","DOI":"10.1007\/s00467-013-2558-9"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013; 122:487-489.","DOI":"10.1097\/AOG.0b013e31828e2612"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol. 2011; 26:1919-1920.","DOI":"10.1007\/s00467-011-1929-3"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Zlamy M, Hofer J, Elias J, Vogel U, Frosch M, Jungraithmayr T, Zimmerhackl LB, Prelog M. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy. Pediatr Transplant. 2012; 16:E246-E250.","DOI":"10.1111\/j.1399-3046.2011.01585.x"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Kim JJ, Goodship TH, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol. 2011; 26:2073-2076.","DOI":"10.1007\/s00467-011-1944-4"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009; 20:940-949.","DOI":"10.1681\/ASN.2008080906"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011; 26:1325-1329.","DOI":"10.1007\/s00467-011-1879-9"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Tran H, Chaudhuri A, Concepcion W, Grimm PC. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol. 2014; 29:477-480.","DOI":"10.1007\/s00467-013-2630-5"},{"key":"80","unstructured":"80. Saland J. Liver-kidney transplantation to cure atypical HUS: Still an option post-eculizumab? Pediatr Nephrol. 2014; 29:329-332."},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, D&apos;Agati VD, Lifton RP, Gharavi AG, Ghiggeri GM, Sanna-Cherchi S. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol. 2014.","DOI":"10.1681\/ASN.2013080886"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/3\/2\/3_2014.01001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T05:11:26Z","timestamp":1649221886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/3\/2\/3_2014.01001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2014.01001","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}